Femoral Fracture (Proximal) Clinical Trial
— ATNOfficial title:
Clinical Trial to Monitor the Clinical Effectiveness of the DePuy ATN Trochanteric Nailing System in the Treatment of Trochanteric Fractures of the Proximal Femur
| NCT number | NCT00546429 |
| Other study ID # | 04077 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | September 1, 2006 |
| Est. completion date | September 1, 2009 |
| Verified date | June 2023 |
| Source | DePuy Orthopaedics |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The purpose of this study is to monitor trochanteric fracture healing and review the performance of the ATN system.
| Status | Completed |
| Enrollment | 62 |
| Est. completion date | September 1, 2009 |
| Est. primary completion date | September 1, 2009 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Ability to understand and willing to sign the approved consent form. - 18 years of age - Skeletally mature - Have stable or unstable proximal femur fracture, including pertrochanteric, intertrochanteric, high subtrochanteric or any combination of the AO Proximal Femur Fracture Classification Exclusion Criteria: - Subjects with concomitant lower extremity injuries or multiple trauma that would interfere with normal hip fracture rehabilitation. - Subjects who have isolated or combined medial femoral neck fractures. - Subjects who are unwilling or unable to comply with a rehabilitation program or are unwilling or unable to be assessed for 1 year following surgery. - Subjects who are pregnant or breastfeeding. - Subjects who are a prisoner or a known alcohol or drug abuser. - Subjects who have a prior surgical history in the affected hip, or conditions that may interfere with outcome or impede healing. - Subjects who have an obliterated medullary canal or other conditions that may complicate the reaming process. - Subjects who have evidence of active untreated infections that may spread to other areas of the body. - Subjects who have a highly communicable disease or pathology that may limit follow-up. - Subjects, who in the opinion of the Clinical Investigator, have an existing condition that indicates the Subject is not a good candidate for the study. - Subjects who are participating in another clinical investigation. - Subjects known to have allergies to titanium, aluminum, vanadium. - Subjects who are currently eligible for workman's compensation. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Blue Ridge Bone and Joint | Asheville | North Carolina |
| United States | Erie County Medical Center | Buffalo | New York |
| United States | Front Range Orthopaedics | Colorado Springs | Colorado |
| United States | Orthopaedic Physicians of Colorado | Englewood | Colorado |
| Lead Sponsor | Collaborator |
|---|---|
| DePuy Orthopaedics |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Success in Terms of the Merle D'Aubigne Postel Score for Pain Category | Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately | 4 weeks, 3, 6 and 12 months | |
| Primary | Success in Terms of the Merle D'Aubigne Postel Score for Walk Category | Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately | 4 weeks, 3, 6 and 12 months | |
| Primary | Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category | Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately | 4 weeks, 3, 6 and 12 months | |
| Secondary | Lower Extremity Measure (LEM) | 4 weeks, 3, 6 and 12 months | ||
| Secondary | Medical Imaging | 4 weeks, 3, 6 and 12 months | ||
| Secondary | Six Item Screener and Ambulatory Status | 4 weeks, 3, 6 and 12 months | ||
| Secondary | SF-12 | 4 weeks, 3, 6 and 12 months |